Open AccessLeukapheresis Does Not Improve Early Survival Outcome of Acute Myeloid Leukemia with Leukostasis Patients – A Dual-Center Retrospective Cohort Study
Author(s) -
Ikhwan Rinaldi,
Resti Mulya Sari,
Vanya Utami Tedhy,
Kevin Winston
Publication year - 2021
Publication title -
journal of blood medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.676
H-Index - 18
ISSN - 1179-2736
DOI - 10.2147/jbm.s312140
Subject(s) - leukostasis , medicine , leukapheresis , hazard ratio , myeloid leukemia , induction chemotherapy , proportional hazards model , retrospective cohort study , surgery , acute leukemia , chemotherapy , confidence interval , leukemia , stem cell , biology , cd34 , genetics
Leukostasis is a medical emergency with high mortality which often occurs in acute myeloid leukemia patients with hyperleukocytosis. One of the therapies that can be used for leukostasis in acute myeloid leukemia is leukapheresis. However, whether leukapheresis can provide better survival benefit when compared with patients not receiving leukapheresis is still unclear. Hence, we aimed to evaluate the effect of chemotherapy plus leukapheresis combination versus chemotherapy only on 28-day survival of acute myeloid leukemia patients with leukostasis.